These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2022 related articles for article (PubMed ID: 33257051)

  • 1. Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies.
    Baburaj G; Thomas L; Rao M
    Arch Med Res; 2021 Apr; 52(3):261-269. PubMed ID: 33257051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repurposed pharmacological agents for the potential treatment of COVID-19: a literature review.
    Kröker A; Tirzīte M
    Respir Res; 2021 Nov; 22(1):304. PubMed ID: 34838020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.
    Singh B; Ryan H; Kredo T; Chaplin M; Fletcher T
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013587. PubMed ID: 33624299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk Assessment of Drug-Induced Long QT Syndrome for Some COVID-19 Repurposed Drugs.
    Michaud V; Dow P; Al Rihani SB; Deodhar M; Arwood M; Cicali B; Turgeon J
    Clin Transl Sci; 2021 Jan; 14(1):20-28. PubMed ID: 32888379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-drug interactions with candidate medications used for COVID-19 treatment: An overview.
    Rezaee H; Pourkarim F; Pourtaghi-Anvarian S; Entezari-Maleki T; Asvadi-Kermani T; Nouri-Vaskeh M
    Pharmacol Res Perspect; 2021 Feb; 9(1):e00705. PubMed ID: 33421347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-drug Interactions between COVID-19 Treatments and Antidepressants, Mood Stabilizers/Anticonvulsants, and Benzodiazepines: Integrated Evidence from 3 Databases.
    Plasencia-García BO; Rico-Rangel MI; Rodríguez-Menéndez G; Rubio-García A; Torelló-Iserte J; Crespo-Facorro B
    Pharmacopsychiatry; 2022 Jan; 55(1):40-47. PubMed ID: 34171927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
    Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
    Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
    Uzunova K; Filipova E; Pavlova V; Vekov T
    Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study.
    Prats-Uribe A; Sena AG; Lai LYH; Ahmed WU; Alghoul H; Alser O; Alshammari TM; Areia C; Carter W; Casajust P; Dawoud D; Golozar A; Jonnagaddala J; Mehta PP; Gong M; Morales DR; Nyberg F; Posada JD; Recalde M; Roel E; Shah K; Shah NH; Schilling LM; Subbian V; Vizcaya D; Zhang L; Zhang Y; Zhu H; Liu L; Cho J; Lynch KE; Matheny ME; You SC; Rijnbeek PR; Hripcsak G; Lane JC; Burn E; Reich C; Suchard MA; Duarte-Salles T; Kostka K; Ryan PB; Prieto-Alhambra D
    BMJ; 2021 May; 373():n1038. PubMed ID: 33975825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC-MS/MS method in human serum.
    Habler K; Brügel M; Teupser D; Liebchen U; Scharf C; Schönermarck U; Vogeser M; Paal M
    J Pharm Biomed Anal; 2021 Mar; 196():113935. PubMed ID: 33548872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of repurposed drugs on the symptomatic COVID-19 patients.
    Hussain I; Hussain A; Alajmi MF; Rehman MT; Amir S
    J Infect Public Health; 2021 Jan; 14(1):24-38. PubMed ID: 33341481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SAveRUNNER: A network-based algorithm for drug repurposing and its application to COVID-19.
    Fiscon G; Conte F; Farina L; Paci P
    PLoS Comput Biol; 2021 Feb; 17(2):e1008686. PubMed ID: 33544720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19.
    Kumar P; Sah AK; Tripathi G; Kashyap A; Tripathi A; Rao R; Mishra PC; Mallick K; Husain A; Kashyap MK
    Mol Cell Biochem; 2021 Feb; 476(2):553-574. PubMed ID: 33029696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.
    Costanzo M; De Giglio MAR; Roviello GN
    Curr Med Chem; 2020; 27(27):4536-4541. PubMed ID: 32297571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small-molecule Antiviral Agents in Ongoing Clinical Trials for COVID-19.
    Apaydın ÇB; Çınar G; Cihan-Üstündağ G
    Curr Drug Targets; 2021; 22(17):1986-2005. PubMed ID: 33588727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety profile of COVID-19 drugs in a real clinical setting.
    Chiu MN; Bhardwaj M; Sah SP
    Eur J Clin Pharmacol; 2022 May; 78(5):733-753. PubMed ID: 35088108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment.
    Marra F; Smolders EJ; El-Sherif O; Boyle A; Davidson K; Sommerville AJ; Marzolini C; Siccardi M; Burger D; Gibbons S; Khoo S; Back D
    Drugs R D; 2021 Mar; 21(1):9-27. PubMed ID: 33336316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of potential drug interactions between repurposed COVID-19 and antitubercular drugs: an integrational approach of drug information software and computational techniques data.
    Thomas L; Birangal SR; Ray R; Sekhar Miraj S; Munisamy M; Varma M; S V CS; Banerjee M; Shenoy GG; Rao M
    Ther Adv Drug Saf; 2021; 12():20420986211041277. PubMed ID: 34471515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repurposing Drugs for COVID-19: An Approach for Treatment in the Pandemic.
    Khadka S; Yuchi A; Shrestha DB; Budhathoki P; Al-Subari SMM; Ziad Alhouzani TM; Anwar Butt I
    Altern Ther Health Med; 2020 Aug; 26(S2):100-107. PubMed ID: 32827400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue distributions of antiviral drugs affect their capabilities of reducing viral loads in COVID-19 treatment.
    Wang Y; Chen L
    Eur J Pharmacol; 2020 Dec; 889():173634. PubMed ID: 33031797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 102.